歐盟5國的MA (醫療事務) 部門的評估:氣喘/COPD

本報告提供處理氣喘/COPD的治療藥主要12項產品的各公司醫療事務 (MA)團隊相關歐盟5國 (法國、義大利、德國、西班牙、英國)的150名呼吸系統科醫生及一般醫生的調查 ，對各公司團隊的效能及滿意度的評分及排行榜，醫生的服務利用趨勢，要求，改善地方分析等彙整資料。

調查目標產品

• Anoro (umeclidinium/vilanterol; GSK)
• Daxas (roflumilast; AstraZeneca)
• Eklira (aclidinium; AstraZeneca)
• Nucala (mepolizumab; GSK)
• Onbrez (indacaterol; Novartis)
• Relvar Ellipta (vilanterol/fluticasone furoate; GSK)
• Seebri (glycopyrronium; Novartis)
• Seretide (fluticasone/salmeterol; GSK)
• Spiriva (tiotropium; Boehringer Ingelheim)
• Symbicort (budesonide/formoterol; AstraZeneca)
• Ultibro (indacaterol/glycopyrronium; Novartis)
• Xolair (omalizumab; Roche/Novartis)

調查、分析內容範例

• 醫生的需求
  • 醫生對MA團隊的利用方法、頻率
  • 認為最重要的服務
  • 最適合的聯繫頻率和途徑
• MA團隊提供的內容
  • 醫生跟團隊的互動印象
  • 醫生對團隊的效能、滿意度排行榜:12項
  • 與其他團隊的比較
• 需要改善的地方等

How well does your asthma/COPD medical affairs team performance compare with the rest?

According to this latest survey of 150 pulmonologists and primary care physicians across the EU5 (UK, France, Germany, Italy and Spain) the performance of asthma/COPD medical affairs teams still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.

Use Medical Affairs Reputations: Asthma/COPD 2017 (EU5) to discover how your team can better meet the high expectations of physicians at the frontline.

This report compares the current activities of medical affairs teams for the 12 leading treatments for asthma/COPD from AstraZeneca, Boehringer Ingelheim, GSK, and Novartis. It shows:

• How physicians rate each team overall, and for 12 key medical affairs services.
• What is most important to physicians, plus what can be done better.
• How, and how often physicians want to meet with your team.

It's time to find out exactly how well your medical affairs team is performing against fierce competition - and establish an action plan to gain competitive advantage.

Interested in the US market? Click here to see the US Edition.

Request sample pages

Top Takeaways

• Tightly bunched at the top. Five teams have leapt ahead with 78-80% of physicians recalling an interaction within the last 6 months. Where does your team sit? At the top or toward the bottom?
• Building confidence. How much do European physicians rely on medical affairs to answer questions about off-label usage? What are they spending more time talking about to medical affairs professionals than ever before?
• Fierce competition. One team has leapt to the top of the satisfaction tables for almost every medical affairs attribute. Which team is it, and what can other teams do to catch up?
• Are doctors embracing digital? Or do physicians prefer face-to-face meetings in their office or at medical conferences? And what's the optimal frequency of these meetings?
• Good news for all. Physicians praised every drug for at least 3 areas of support provided by medical affairs.
• Information is king. 35% of respondents want to know more from their medical affairs teams. What specifically are they asking for?

Insight into Medical affairs teams for these asthma/COPD treatments

• Anoro (umeclidinium/vilanterol; GSK)
• Daxas (roflumilast; AstraZeneca)
• Eklira (aclidinium; AstraZeneca)
• Nucala (mepolizumab; GSK)
• Onbrez (indacaterol; Novartis)
• Relvar Ellipta (vilanterol/fluticasone furoate; GSK)
• Seebri (glycopyrronium; Novartis)
• Seretide (fluticasone/salmeterol; GSK)
• Spiriva (tiotropium; Boehringer Ingelheim)
• Symbicort (budesonide/formoterol; AstraZeneca)
• Ultibro (indacaterol/glycopyrronium; Novartis)
• Xolair (omalizumab; Roche/Novartis)

A Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of medical affairs teams for 12 leading asthma/COPD brands-answering important questions like:

What do physicians need?

• How, and how often are they using your medical affairs team?
• What services do they consider most important?
• How often should you contact them? What channels are best?

Does your medical affairs team deliver?

• How memorable are your team's interactions with doctors?
• How do doctors rank your team for performance and satisfaction in 12 key areas?
• How does your team compare to the competition-in each area, and overall?

What needs improvement?

• Are you delivering the services that are most important to doctors?
• Where do you need to improve?
• How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 pulmonologists and primary care physicians from the EU5 (France, Italy, Germany, Spain, UK) chosen from the largest community of validated physicians in the world

All respondents:

• Have been practicing for between 3 and 35 years
• See at least 5 asthma/COPD patients a typical month
• Devote at least 50% of their time to direct patient care
• Have interacted with at least one listed product's medical affairs team in the past 6 months.

We conducted the survey between September 1-14, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Table of Contents

1. Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary

2. Current Status of Interactions with Different Medical Affairs Teams

• 2.1 Interactions in the past 6 months with Medical Affairs teams for each product
• 2.2 Current frequency of interactions with medical affair teams for each product

3. Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes

• 3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
• 3.2 Attribute importance of Medical Affairs teams roles to physicians' practice
• 3.3 EdgeMap analysis - Competitive evaluation on Medical Affairs teams performance on attributes
• 3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
• 3.5 Need-Gap analysis by product

4. Preferred Interaction Media, Frequency, and Suggestions for Improvement

• 4.1 Preferred interaction media and frequency, and suggestions for improvement

5. Appendix